Glaxosmithkline Pharmaceuticals Ltd.
Snapshot View

1728.40 +46.65 ▲2.8%

26 July 2021, 04:02:12 P.M.
Volume: 258,069

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.gsk-india.com
Financial Indicators
Market Cap 29,242.87 Cr.
Earnings per share (EPS) 21.14 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 81.65 Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share 88.49 Trailing Twelve Months Ending 2021-03
Price to Book Value 19.51 Calculated using Price: 1,726.20
Dividend Yield 1.74 Period Ending 2021-03
No. of Shares Subscribed 16.94 Cr. 169,406,034 Shares
FaceValue 10
Company Profile

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.

With the combined heritage of Glaxo Wellcome plc and SmithKline Beecham plc, the company has played a pivotal role in the growth of the healthcare industry for almost a century. GSK has been a leader in India since inception, with a history replete with breakthrough innovations. Through the years, it has set benchmarks in conducting business responsibly, including the ways in which it research, develop, sell, and market its products.

The company is headquartered in Mumbai with various regional and sales hubs across the country. The company has made substantial investments in one large manufacturing facility in Nashik, in the state of Maharashtra.

Business area of the company

The company is engaged in research, manufacture and make available a broad range of medicines and vaccines that benefit people. The company’s Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in anti-infectives and dermatology. Its R&D approach focuses on science related to the immune system, use of genetics and advanced technologies. Meanwhile, Its Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. The company is the leaders in India in the private segment.

Products

  • Medicines
  • Vaccines
  • Prescribing Information
  • Child-resistant packaging

Award and recognition

2017: 

  • Pharma & Medical Devices Summit & Excellence Awards 2017
  • GSK India wins the Gold Award at the TISS - CLO Summit
  • GSK India won the 'Gold award' in the Sales Enablement Category at the Tata Institute of Social Sciences (TISS) - CLO Summit in Mumbai.

2018:

  • GSK ranked among the 50 best companies in India as per People Capital Index (PCI). GSK was conferred this recognition at the HR Leadership Summit 2018.
  • GSK won the OPPI Salesforce Excellence Award 2018. The award recognises its efforts in launching and scaling an innovative, mobile based platform for sales readiness.
  • Tbact bags the Silver award for ‘Brand of the Year - Acute category 2018’ for marketing excellence. This award is a testimony to Teamwork and accountability displayed by each member of the cross functional team associated with Tbact.
  • The company has been recognised as one of the 100 Best Companies for Women by Working Mother and AVTAR. The award was received by members of the Women's Leadership Board.
  • GSK topped the Access to Medicine Index (ATMI) for the sixth time in a row. ATMI is an independent measure of the top 20 pharmaceutical companies’ efforts to improve access to healthcare in developing countries.
  • GSK's Corporate Communication and Government Affairs team was recognised by Reputation Today as the 30 Top Corporate Communication Teams in India.
  • The company has been recognised as one of the 100 Best Companies for Women by Working Mother and AVTAR for the second time in a row. This is an important milestone in its inclusion and diversity journey.
  • GSK has been recognised as the 'Best Workplaces for Women' by Great Places To Work in India. This award celebrates the efforts of the company's Women's Leadership Initiative towards creating an inclusive work environment.

2019:

  • GSK won the 2019 D&I in India Best Practices Awards in the 'Advancement of Women' category by Community Business.
  • GSK won the award for the 'Best Sales and Operations Planning Practice in Pharma' 2019.
  • T-Bact won 'Brand of the Year' award in the acute category for the second consecutive year in 2019 at the 6th AWACS Awards for marketing excellence.

2020: 

  • GSK was recognised as India’s Best Workplaces for Women 2020 by Great Places to Work
  • GSK was recognised as 100 Best Companies for Women in India 2020 by Working Mother and AVTAR

Milestones

  • 1924: Glaxo comes to India as H J Foster and Co.
  • 1947: Secondary manufacturing of pharmaceuticals begins at Glaxo’s Worli plant.
  • 1956: Primary production of vaccines begins at Worli plant.
  • 1968: Glaxo is registered as Limited company.
  • 1972: Scientists at Beecham Research laboratories discover Amoxycillin and launch Amoxil, which eventually becomes a widely used antibiotic.
  • 1981: Augmentin was launched by Beecham to combat a wide range of bacterial infections in children and adults and the antiviral Zovirax was launched by Wellcome for harpes infections.
  • 1983: Glaxo’s Nashik factory commissioned.
  • 1999: Glaxo India completes 75 years in India it is ranked ‘India’s most respective company’ by business world and again in 2003.
  • 2001: Legal merger of Glaxo India Limited and SmithKline Beecham Pharmaceuticals (India) Limited to form GlaxoSmithKline Pharmaceuticals Limited.
  • 2015: GSK acquired Novartis vaccines business (excluding influenza vaccines).
  • 2016: Launched Priorix- Tetra.
  • 2018: Launched Infanrix Hexa.
  • 2019: Launched Menveo (Quadrivalent Meningococcal Conjugate Vaccine).
  • 2019: The company has launched Spectrum, an employee resource group for raising awareness on LGBT+ among the employees.
  • 2019: Launched a development programme GSK WeLeAP - GSK Women Leadership Action Programme - to develop high potential mid-level women talent.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.77%
1 Week
+7.52%
1 Month
+14.10%
3 Month
+19.11%
6 Month
+16.16%
1 Year
+17.09%
2 Year
+43.87%
5 Year
+1.95%
9 years 2012-12 2013-12 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 28.50 24.10 24.95 18.75 16.08 17.26 21.22 4.71 21.58
Return on Capital Employed (%) 42.24 35.54 39.53 28.81 24.39 26.56 32.54 15.76 33.38
Return on Assets (%) 18.82 15.95 15.44 7.84 5.16 4.93 5.77 1.72 11.87

Balance Sheet View Details

Particulars 9 years 2012-12 Rs. Cr. 2013-12 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 2,007 1,990 1,829 2,183 2,007 2,057 2,140 1,821 1,499
Non Curr. Liab. 158 159 197 3,498 3,700 2,632 2,860 180 179
Curr. Liab. 836 889 1,107 784 881 2,949 2,804 1,022 1,332
Minority Int.
Equity & Liab. 3,002 3,037 3,133 6,465 6,588 7,639 7,804 3,023 3,010
Non Curr. Assets 355 413 546 4,087 4,753 4,103 4,445 1,248 808
Curr. Assets 2,647 2,624 2,587 2,378 1,835 3,536 3,359 1,775 2,203
Misc. Exp. not W/O
Total Assets 3,002 3,037 3,133 6,465 6,588 7,639 7,804 3,023 3,010

Profit Loss View Details

Particulars 9 years 2012-12 Rs. Cr. 2013-12 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 2,692 2,608 3,363 2,838 2,908 2,871 3,128 3,224 3,199
Other Income 224 222 259 123 73 55 102 79 111
Total Income 2,916 2,830 3,622 2,961 2,982 2,926 3,230 3,303 3,309
Total Expenditure -1,915 -2,124 -2,788 -2,360 -2,489 -2,366 -2,527 -2,567 -2,504
PBIDT 1,001 706 833 601 492 560 703 736 806
Interest 0 0 0 0 0 0 -1 -6 -4
Depreciation -18 -20 -25 -25 -26 -38 -49 -83 -79
Taxation -272 -230 -279 -202 -174 -189 -237 -213 -192
Exceptional Items -148 26 -52 2 46 18 29 -341 -173
PAT 562 482 476 376 337 351 445 93 358

Cash Flow View Details

Particulars 9 years 2012-12 Rs. Cr. 2013-12 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 314 281 338 139 234 473 409 491 578
Cash Fr. Inv. -110 189 180 499 301 -104 -153 -57 419
Cash Fr. Finan. -441 -494 -497 -638 -511 -307 -358 -428 -696
Net Change -237 -24 21 0 24 62 -102 6 300
Cash & Cash Eqvt 138 114 116 115 139 201 99 105 405

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 75.00 75.00 75.00 75.00 75.00 75.00 75.00 75.00 75.00
Public 25.00 25.00 25.00 25.00 25.00 25.00 25.00 25.00 25.00
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 09 Jul 2021
Updates
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding 'Certificate pursuant to Regulation 74(5) of SEBI (Depositories andParticipants) Regulations, 2018 for the quarter ended 30th June 2021'.
Wed, 07 Jul 2021
Copy of Newspaper Publication
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Tue, 06 Jul 2021
Copy of Newspaper Publication
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

Technical Scans View Details

Mon, 26 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Increasing Relative Strength - Benchmark index Increasing Relative Strength - Benchmark index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%